← Back

Wire · opportunities

Sanofi gets Genzyme asset across FDA finish line with key nod in Gaucher type 3

Published

20 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercepharma.com →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

Sanofi received FDA approval for its oral drug Infilbray (venglustat) to treat neurological symptoms of type 3 Gaucher disease, filling a treatment gap beyond existing enzyme replacement therapies. The approval was based on positive phase 3 trial results demonstrating improvement in neurological function and cognition in patients.

This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 18 Nov 2026 and 20 Nov 2026.

◆ ◆ The Wire takeaway

You can now develop treatments targeting neurological symptoms in rare diseases where systemic therapies fall short. The FDA’s green light for Sanofi’s oral drug opens a route for precision therapies that cross the blood-brain barrier.

◆ Coverage

7 sources · first reported 18 Nov 2026 · latest 20 Nov 2026

◆ Related on Wire

◆ Topics

Biotechrare-diseasedrug-approvalneurological-treatmentsanofigaucher-disease